Research programme: prostaglandin F2 alpha receptor antagonists - ObsEva

Drug Profile

Research programme: prostaglandin F2 alpha receptor antagonists - ObsEva

Alternative Names: AS-604872; OBE 002

Latest Information Update: 30 Oct 2014

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Merck Serono
  • Developer Merck Serono; ObsEva
  • Class Biphenyl compounds; Small molecules; Sulfonamides; Thiazolidines
  • Mechanism of Action Prostaglandin F2 alpha antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Dysmenorrhoea; Preterm labour

Most Recent Events

  • 30 Oct 2014 Discontinued - Preclinical for Preterm labour in USA (PO)
  • 30 Oct 2014 Preclinical trials in Dysmenorrhoea in Switzerland (PO)
  • 30 Oct 2014 Preclinical trials in Preterm labour in Switzerland (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top